Quantcast

Latest Tuberculosis treatment Stories

2008-10-27 09:00:12

SAN FRANCISCO, Oct. 27 /PRNewswire/ -- 5:00 AM PST -- UCB announced today results from several Phase III clinical trials evaluating CIMZIA(R) (certolizumab pegol) - the only PEGylated anti-TNF (Tumor Necrosis Factor) - presented at the American College of Rheumatology (ACR) Annual Scientific Meeting. Results from the open-label extension study to RAPID 1 met both co-primary endpoints (American College of Rheumatology (ACR) 20 response(a) scores at Week 24 and change from baseline in modified...

2008-10-16 12:00:25

Genzyme, a biotechnology company, has started enrollment in a world-wide post-marketing clinical trial evaluating the efficacy and safety of treating pediatric male patients with mild Fabry disease symptoms with a low-dose regimen of Fabrazyme. Approximately 20 institutions across Europe, the US, Canada and Latin America are expected to participate in the study. The trial will examine the efficacy and safety of two lower-dose regimens of Fabrazyme in male patients aged five to 18 years over...

2008-10-06 09:00:09

ORLANDO, Fla., Oct. 6 /PRNewswire/ -- UCB today presented data from a large, prospective study investigating endoscopic improvement in Crohn's disease (CD) with a biologic compound. The data presented at the American College of Gastroenterology Annual Scientific Meeting demonstrates that CIMZIA(R) (certolizumab pegol) -- the only PEGylated anti-TNF alpha (Tumor Necrosis Factor alpha) -- significantly improved endoscopic lesions and induced endoscopic response (as assessed by the Crohn's...

2008-10-03 00:00:06

U.S. researchers have determined that Mycobacterium tuberculosis has learned through evolution to coat itself with a sugar called mannose. This sugar makes the bacterium attractive to cells in the lungs that are looking to clean up and discard unwanted sugar in the body. Those lung cells absorb the TB bacteria, giving the infecting bacteria a place to live for the long term, Ohio State University researchers said. "The bug sugarcoats itself and creates this magical interaction that allows...

2008-09-27 03:00:33

By John Canalis LONG BEACH - A single case of tuberculosis has been confirmed at Wilson High School, city health officials said Friday. Authorities would not identify the victim or say if the infected party was a student, teacher, staff member or volunteer. "One individual has active tuberculous," said Dr. Helene Calvet, city health officer. A number of students and staff "may have had significant exposure," to the infected party, according to a statement from the Long Beach...

2008-09-26 15:00:14

By HILL, Ruth HEALTH officials have broadened their search for people who may have been infected by a rare, aggressive form of tuberculosis that killed an Auckland woman before it was diagnosed. Auckland District Health Board began tests this week on about 240 staff and up to 20 patients who came into contact with the woman during her several-week stay in Auckland City Hospital. Chief medical officer David Sage said the board was still tracking patients who were in hospital at the...

2008-09-26 00:00:31

Health officials in New Zealand are looking for anyone who may have been exposed to a woman with an aggressive form of tuberculosis. The Auckland District Health Board said it was testing 240 staff members and up to 20 patients who came into contact with the woman while she was at Auckland City Hospital, the Dominion Post reported Thursday. Lab tests have only recently confirmed that the woman, who died several weeks ago, had a rare form of TB, the newspaper said.

2008-09-15 09:00:57

By Graeme Hetherington A DOCTOR is working with HIV and TB patients in the remote heart of Africa with the support of a North-East charity. Dr Paul Williams is trying to raise the money for an ambulance to work out of the hospital he helps run in one of the remotest region?s of Uganda, and is being helped by Everyday Language Solutions (ELS), based in Thornaby, near Stockton. The charity has a long history of working with Dr Williams, dating from when he practised at the Arrival Medical...

2008-08-28 12:01:22

LEUVEN, Belgium, August 28 /PRNewswire-FirstCall/ -- ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on innovative treatments for eye disease, vascular disease and cancer, is today issuing a business update and its financial results for the six month period ending June 30, 2008. During the first half of 2008, ThromboGenics has achieved a number of key milestones which have positioned the Company to successfully pursue the next stage of its corporate strategy. In...

2008-08-26 15:00:18

By Aggarwal, Deepak Mohapatra, P R; Rekha, V V Banu; Balasubramanian, R; Swaminathan, S; Ramachandran, R; Rahman, F; Sundaram, V; Thyagarajan, K; Selvakumar, N; Adhilakshmi, A R; Iliayas, S; Narayanan, P R Sir, Banu Rekha and colleagues' in their study found that at the end of intensive phase of tuberculosis treatment among sputum positive cases, the smear conversion rates were 58, 61, 62 per cent and culture conversion 86, 88 and 92 per cent respectively. Also, the patients with HIV...


Word of the Day
tesla
  • The unit of magnetic flux density in the International System of Units, equal to the magnitude of the magnetic field vector necessary to produce a force of one newton on a charge of one coulomb moving perpendicular to the direction of the magnetic field vector with a velocity of one meter per second. It is equivalent to one weber per square meter.
This word is named for Nikola Tesla, the inventor, engineer, and futurist.